Organ support & nutrition

Immune profiling of critically ill patients with acute kidney injury during the first week after various types of injuries: the REALAKI study

Crit CarePublished Ancillary analysis of the REAnimation Low Immune Status Marker (REALISM) prospective cohort study

Authors' conclusion

Following various types of severe injuries, early AKI is associated with the initial inflammatory response. Presence of AKI at the end of the first week after injury is associated with injury-induced immunosuppression.

Study context

Population
Critically ill ICU patients after sepsis, trauma, surgery or burns; end-stage renal disease excluded
Participants
359 patients · 3 ICUs
Exposure
Acute kidney injury (AKI) vs no AKI
  • AKIn = 139
Outcome
Association between immune profiles and AKI (including persistent AKI) during the first week after admission
Follow-up
D1-2, D3-4, D5-7
Methodological detailsmulticentre (3 ICUs), multivariable logistic regression
  • Multicentre (3 ICUs)
  • Multivariable logistic regression

Main finding

As reported in the abstract

Immunological parameters independently associated with AKI (multivariable logistic regression)
AKI vs No AKIOdds ratio (CI)P value
D1-2; CD10lowCD16low immature neutrophils
3.03(1.7–5.5)
P < 0.001
D5-7; increased IL-10 levels
1.38(1.12–1.71)
P = 0.001
D5-7; ex vivo TNF-α production after LPS stimulation
0.51(0.27–0.91)
P = 0.03

Observational data: associations, not effects.

Further findings

AKI incidence and persistence

AKI at D1-2
139 (39%)
AKI at D5-7
61 (20%)
Persistent AKI at D5-7
94%

Recovery from AKI between D1-2 and D5-7 vs persistent AKI

Patients who recovered tended to correct the immune alterations

Original publication

Immune profiling of critically ill patients with acute kidney injury during the first week after various types of injuries: the REALAKI study. Crit Care. Published 8 July 2024. doi:10.1186/s13054-024-04998-w

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.